JP2014500873A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014500873A5 JP2014500873A5 JP2013538984A JP2013538984A JP2014500873A5 JP 2014500873 A5 JP2014500873 A5 JP 2014500873A5 JP 2013538984 A JP2013538984 A JP 2013538984A JP 2013538984 A JP2013538984 A JP 2013538984A JP 2014500873 A5 JP2014500873 A5 JP 2014500873A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- fusion protein
- fgfr1
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41394010P | 2010-11-15 | 2010-11-15 | |
| US61/413,940 | 2010-11-15 | ||
| US42146210P | 2010-12-09 | 2010-12-09 | |
| US61/421,462 | 2010-12-09 | ||
| PCT/US2011/060661 WO2012068030A1 (en) | 2010-11-15 | 2011-11-14 | Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016175357A Division JP2017019843A (ja) | 2010-11-15 | 2016-09-08 | 高用量の可溶性fgfr1融合タンパク質を用いるがんの治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014500873A JP2014500873A (ja) | 2014-01-16 |
| JP2014500873A5 true JP2014500873A5 (cg-RX-API-DMAC7.html) | 2014-12-25 |
| JP6178240B2 JP6178240B2 (ja) | 2017-08-09 |
Family
ID=44993965
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538984A Expired - Fee Related JP6178240B2 (ja) | 2010-11-15 | 2011-11-14 | 高用量の可溶性fgfr1融合タンパク質を用いるがんの治療 |
| JP2013538985A Expired - Fee Related JP5945277B2 (ja) | 2010-11-15 | 2011-11-14 | Fgfr1細胞外ドメイン併用療法 |
| JP2016106022A Pending JP2016196475A (ja) | 2010-11-15 | 2016-05-27 | Fgfr1細胞外ドメイン併用療法 |
| JP2016175357A Pending JP2017019843A (ja) | 2010-11-15 | 2016-09-08 | 高用量の可溶性fgfr1融合タンパク質を用いるがんの治療 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538985A Expired - Fee Related JP5945277B2 (ja) | 2010-11-15 | 2011-11-14 | Fgfr1細胞外ドメイン併用療法 |
| JP2016106022A Pending JP2016196475A (ja) | 2010-11-15 | 2016-05-27 | Fgfr1細胞外ドメイン併用療法 |
| JP2016175357A Pending JP2017019843A (ja) | 2010-11-15 | 2016-09-08 | 高用量の可溶性fgfr1融合タンパク質を用いるがんの治療 |
Country Status (14)
| Country | Link |
|---|---|
| EP (2) | EP2640377B1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP6178240B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR101910779B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN107050426A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2011329125B2 (cg-RX-API-DMAC7.html) |
| BR (2) | BR112013012040A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2817537A1 (cg-RX-API-DMAC7.html) |
| EA (2) | EA025828B1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL226248A0 (cg-RX-API-DMAC7.html) |
| MX (2) | MX349293B (cg-RX-API-DMAC7.html) |
| NZ (4) | NZ610487A (cg-RX-API-DMAC7.html) |
| SG (2) | SG190248A1 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2012068032A1 (cg-RX-API-DMAC7.html) |
| ZA (2) | ZA201303501B (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| WO2013074492A1 (en) | 2011-11-14 | 2013-05-23 | Five Prime Therapeutics, Inc. | Methods of treating cancer |
| CA2908391A1 (en) * | 2013-05-01 | 2014-11-06 | Five Prime Therapeutics, Inc. | Methods of treating cancer |
| WO2014190147A2 (en) * | 2013-05-23 | 2014-11-27 | Five Prime Therapeutics, Inc. | Methods of treating cancer |
| EA034376B1 (ru) * | 2013-07-05 | 2020-01-31 | Интегра Медикал Инк. | Композиции для оздоровления полости рта |
| WO2015066452A2 (en) * | 2013-11-01 | 2015-05-07 | Foundation Medicine, Inc. | Methods of treating pediatric cancers |
| MX394623B (es) | 2016-02-04 | 2025-03-24 | Ads Therapeutics Llc | Tecnología de sinergismo anticuerpo-fármaco para el tratamiento de enfermedades. |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US5288855A (en) | 1989-01-23 | 1994-02-22 | Farmitalia Carlo Erba | Extracellular form of the human fibroblast growth factor receptor |
| WO1991000916A2 (en) | 1989-07-06 | 1991-01-24 | The Regents Of The University Of California | Receptors for fibroblast growth factors |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| ATE243253T1 (de) | 1990-07-06 | 2003-07-15 | Rhone Poulenc Rorer Internat H | Rezeptoren der wachstumsfaktoren aus fibroblasten |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US5229501A (en) | 1991-01-11 | 1993-07-20 | Chiron Corporation | Expression and use of human fibroblast growth factor receptor |
| AU1674292A (en) | 1991-03-15 | 1992-10-21 | Synergen, Inc. | Pegylation of polypeptides |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| KR100335584B1 (ko) | 1992-10-28 | 2002-11-29 | 제넨테크, 인코포레이티드 | 혈관내피세포성장인자에대한길항제 |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| CN104231078A (zh) | 1997-04-07 | 2014-12-24 | 基因技术股份有限公司 | 抗-血管内皮生长因子的抗体 |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| DE69829891T2 (de) | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF Antikörper |
| AU6366999A (en) | 1998-10-30 | 2000-05-22 | Takeda Chemical Industries Ltd. | Betacellulin protein-containing preparations |
| WO2000046380A2 (en) | 1999-02-08 | 2000-08-10 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| PT1292335E (pt) | 2000-06-23 | 2007-08-13 | Bayer Schering Pharma Ag | Combinações e composições que interferem na função de receptores vegf/vegf e angiopoietina/ tie e a sua utilização (ii) |
| US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| KR100976076B1 (ko) | 2003-05-22 | 2010-08-17 | 아보트 러보러터리즈 | 인다졸, 벤즈이속사졸 및 벤즈이소티아졸 키나제 억제제 |
| RS20150135A1 (sr) | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
| WO2006076288A2 (en) | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Dna constructs for long-term expression of intravascularly injected naked dna |
| WO2006081430A2 (en) | 2005-01-27 | 2006-08-03 | Five Prime Therapeutics, Inc. | Leader sequences for directing secretion of polypeptides and methods for production thereof |
| NZ565511A (en) | 2005-07-22 | 2011-03-31 | Five Prime Therapeutics Inc | Compositions and methods of treating disease with FGFR fusion proteins |
| PE20081250A1 (es) | 2006-11-28 | 2008-10-07 | Centelion | FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA |
| ZA200903134B (en) * | 2006-11-28 | 2010-08-25 | Centelion | Modified soluble FGF receptor FC fusions with improved biological activity |
| TWI468417B (zh) | 2007-11-30 | 2015-01-11 | Genentech Inc | 抗-vegf抗體 |
| PT2498799T (pt) * | 2009-11-13 | 2016-11-04 | Five Prime Therapeutics Inc | Utilização de proteínas do domínio extracelular rfcf1 para tratar cancros caracterizados por mutações ativadoras dependentes de ligando em rfcf2 |
-
2011
- 2011-11-14 MX MX2013005387A patent/MX349293B/es active IP Right Grant
- 2011-11-14 BR BR112013012040A patent/BR112013012040A2/pt not_active IP Right Cessation
- 2011-11-14 EA EA201390716A patent/EA025828B1/ru not_active IP Right Cessation
- 2011-11-14 JP JP2013538984A patent/JP6178240B2/ja not_active Expired - Fee Related
- 2011-11-14 BR BR112013012041A patent/BR112013012041A2/pt not_active IP Right Cessation
- 2011-11-14 KR KR1020187012882A patent/KR101910779B1/ko not_active Expired - Fee Related
- 2011-11-14 EP EP11784918.2A patent/EP2640377B1/en active Active
- 2011-11-14 NZ NZ610487A patent/NZ610487A/en not_active IP Right Cessation
- 2011-11-14 CN CN201710017991.8A patent/CN107050426A/zh active Pending
- 2011-11-14 CA CA2817537A patent/CA2817537A1/en not_active Abandoned
- 2011-11-14 WO PCT/US2011/060666 patent/WO2012068032A1/en not_active Ceased
- 2011-11-14 AU AU2011329125A patent/AU2011329125B2/en not_active Ceased
- 2011-11-14 EP EP11790705.5A patent/EP2640406A1/en not_active Withdrawn
- 2011-11-14 WO PCT/US2011/060661 patent/WO2012068030A1/en not_active Ceased
- 2011-11-14 SG SG2013036355A patent/SG190248A1/en unknown
- 2011-11-14 SG SG2013036348A patent/SG190788A1/en unknown
- 2011-11-14 EA EA201390722A patent/EA201390722A1/ru unknown
- 2011-11-14 KR KR1020137015424A patent/KR20130114676A/ko not_active Ceased
- 2011-11-14 NZ NZ703919A patent/NZ703919A/en not_active IP Right Cessation
- 2011-11-14 CN CN201180064851.7A patent/CN103347514B/zh not_active Expired - Fee Related
- 2011-11-14 AU AU2011329127A patent/AU2011329127B2/en not_active Ceased
- 2011-11-14 NZ NZ703786A patent/NZ703786A/en not_active IP Right Cessation
- 2011-11-14 MX MX2013005388A patent/MX2013005388A/es unknown
- 2011-11-14 NZ NZ610538A patent/NZ610538A/en not_active IP Right Cessation
- 2011-11-14 CA CA2817583A patent/CA2817583A1/en not_active Abandoned
- 2011-11-14 KR KR1020137015394A patent/KR20130124513A/ko not_active Ceased
- 2011-11-14 JP JP2013538985A patent/JP5945277B2/ja not_active Expired - Fee Related
-
2013
- 2013-05-09 IL IL226248A patent/IL226248A0/en unknown
- 2013-05-09 IL IL226252A patent/IL226252B/en active IP Right Grant
- 2013-05-14 ZA ZA2013/03501A patent/ZA201303501B/en unknown
- 2013-05-16 ZA ZA2013/03573A patent/ZA201303573B/en unknown
-
2016
- 2016-05-27 JP JP2016106022A patent/JP2016196475A/ja active Pending
- 2016-09-08 JP JP2016175357A patent/JP2017019843A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bouattour et al. | Recent developments of c‐Met as a therapeutic target in hepatocellular carcinoma | |
| US12459974B2 (en) | Bicyclic peptide ligands specific for Nectin-4 | |
| Lieu et al. | Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis | |
| Doycheva et al. | Systemic therapy for advanced hepatocellular carcinoma: an update of a rapidly evolving field | |
| JP2024010052A (ja) | 組織石灰化の治療方法 | |
| JP2014526441A5 (cg-RX-API-DMAC7.html) | ||
| MX2013005294A (es) | Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas. | |
| AU2015255752B2 (en) | Methods and compositions for treating Cystic Fibrosis | |
| JP2018140999A (ja) | アデノウイルスを用いた治療方法 | |
| Seystahl et al. | Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma? | |
| Jitawatanarat et al. | Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib | |
| EA201390722A1 (ru) | Лечение рака повышенными дозами растворимых белков слияния fgfr1 | |
| WO2007120690A2 (en) | Combination histamine h1r and h4r antagonist therapy for treating pruritus | |
| JP5433581B2 (ja) | 非定型抗精神病薬の使用に関連した体重増加を遅延させるための製薬組成物 | |
| BRPI0812835B1 (pt) | Combinações e produtos contendo um agente inibidor de vegf e do irinotecano. | |
| JP2013543870A5 (cg-RX-API-DMAC7.html) | ||
| Li et al. | Enhanced expression of Vastatin inhibits angiogenesis and prolongs survival in murine orthotopic glioblastoma model | |
| EP2285416B1 (en) | Conjugates for the treatment of mesothelioma | |
| Korpanty et al. | Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress? | |
| Lemieux et al. | Targeting the fibroblast growth factor receptors for the treatment of cancer | |
| Wang et al. | New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond | |
| CN115427056A (zh) | 使用actriib配体陷阱和菲卓替尼治疗贫血的方法 | |
| Ciccozzi et al. | cAsɛ sruov | |
| WO2012019192A2 (en) | Cell-permeable molecules as growth factor receptor antagonists | |
| JP2016509018A5 (cg-RX-API-DMAC7.html) |